Mending A Poor Reputation With FDA An Uphill Battle For Firms – But It Can Be Done
This article was originally published in The Silver Sheet
Manufacturers can develop a bad reputation with FDA for a variety of reasons, including failing to systemically fix problems or follow through on commitments. “It’s tiresome, frankly, as a regulator, to have firms come in and pay lip service to the steps that they’re going to take, and then not follow up to demonstrate that they’ve taken those steps,” said CDRH Office of Compliance Director Steven Silverman. In addition, two former agency officials explain why FDA doesn’t trust some companies. “As promises that are made to the agency are broken, or when there is a failure to seriously strive to correct violations, this leads to FDA mistrust, no question about it,” said Larry Spears, now a director for consulting firm Deloitte. A Gambro Renal Products official, who now works at Medtronic, tells how Gambro staff worked to change FDA’s perception of the company after it imposed an import ban on the firm in 2006.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.